Exclusive HCV Interview: Julio Gutierrez, MD

So my first question is what do you see as the biggest challenges associated with the hepatitis C epidemic in the U.S.? JULIO GUTIERREZ: There are three main challenges currently associated with eradicating hepatitis C in the United States: Most patients in the US are still not receiving care for their hepatitis C infection. In order to cure HCV in these patients, they must be tested and referred for therapy. The availability of DAAs is ...

Read More


Exclusive Hepatitis C Interview: Daryl Luster

So my first question is, can you please tell me a little bit about yourself? DARYL LUSTER: Oh, gosh, what’s to tell? I’m 61 this month. Regarding my background, if somebody had said to me 10, even 15 years ago, that I would be involved in health advocacy, I would have said, huh?  No. Really? So it’s been a real shift for me. I come from a business background. I’ve been in business for most of my life.  When I say business, I mean ...

Read More


Exclusive HCV Interview: Lucinda K Porter, RN

Please tell me a little bit about yourself. LUCINDA: I was a patient who was infected with hepatitis C in 1988, and I turned that into an opportunity to learn more about hepatitis C. I have been working in this field since 1997. Along the way, I worked at Stanford Medical Center in their Hepatology Division. I’ve also done a lot of writing since the late ’90s, and I wrote two books, both of them on hepatitis C. Currently, I work as a ...

Read More


Key AASLD 2015 HCV Abstracts: Dr. Lebovics

For more information on the selected AASLD 2015 HCV abstracts below and others to be presented at The International Liver Congress™, please click here to review the Congress abstract e-book. Decreased work productivity in patients with chronic hepatitis C Abstract 18 Reduced Work Productivity (WP), Absenteeism and Presenteeism of Patients Infected with Hepatitis C Virus (HCV) are Independently Predicted by Physical Component of ...

Read More


Decentralized HCV Treatment is Effective!

Given the safety, tolerability, simplicity, and efficacy of hepatitis C direct-acting antiviral (DAA) regimens, decentralizing treatment from gastroenterologists and hepatologists to other specialists, community-based primary care physicians, or appropriately supervised mid-level providers (ie, task-shifting) may be an effective strategy to increase treatment rates, cure rates, and really start addressing to the HCV epidemic. The SVR-12 rates ...

Read More


New HCV Peer-Reviewed PDFs For Free!

For one month only! HCV Peer-Reviewed PDF Bonanza!!! To satisfy your educational needs, Elsevier Multimedia Publishing has made available another 18 new, peer-reviewed, full text articles for free! Please see below for a list of these articles, which can readily be accessed in our American Journal of Medicine Hepatitis C Resource Center (hepcresource.amjmed.com). Note that these free, full text HCV peer-reviewed articles will be ...

Read More


C-SALVAGE: Final 24-week Follow-up Results

Non-cross-resistant drugs are needed for salvage therapy of patients with chronic hepatitis C virus infection who do not achieve sustained virologic response on direct acting antiviral (DAA) regimens. The final follow-up week 24 results from the C-SALVAGE study (Hepatitis C-Salvage Study for Patients who Failed DAA/PR Therapy), have been published in the journal Clinical Infectious Diseases (Buti M, et al. Clin Infect Dis. 2015 Sep 14. [Epub ...

Read More


HCV Drug Costs: A Treatment Access Barrier

In a newly published, thought-provoking article in the journal Clinical Infectious Diseases, Stacey B. Trooskin and colleagues discuss how the high cost of newer hepatitis C therapies has become a major treatment access barrier in the US (Trooskin SB, et al. Clin Infect Dis. 2015 Aug 12 [Epub ahead of print]). Controversial insurance coverage restrictions and treatment rationing has resulted in national patient advocacy mobilization, US Congre...

Read More


Tx Options for HCV GT 1 or 4 Non-responders

New study shows that genotype 1- or 4-infected non-responders, including patients with cirrhosis, achieve high SVR12 rates on the 24 week, quad treatment regimen of daclatasvir plus asunaprevir and peginterferon/ribavirin. The combination was well tolerated and no additional safety and tolerability concerns were observed compared with peginterferon/ribavirin regimens. A combination of Direct Acting Antivirals (DAAs) and peginterferon/ribavirin ...

Read More


Two DAA regimen in cirrhotic HCV GT1b patients

New Phase 2 clinical trial results indicate that an all-oral interferon- and ribavirin-free regimen of ombitasvir, paritaprevir, and ritonavir is generally well tolerated and associated with high rates of SVR12 in both cirrhotic and noncirrhotic patients with HCV genotype 1b infection who were treatment-naive or treatment experienced, including prior null responders, a population for whom antiviral treatment information has been lacking. HCV ...

Read More